BioSpace News Archive

IQ4I Research & Consultancy published a new report on “Infectious Disease Diagnostics Global Market – Forecast To 2026".

Insmed Incorporated, a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, announced the granting of inducement awards to five new employees.

Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of molecular technologies designed to provide physicians with clinically actionable information to improve the outcomes of patients with cancer, announces that it is relocating its corporate offices and CLIA-certified, CAP-accredited high complexity laboratory to a new location i

Avenue Therapeutics, Inc. (NASDAQ: ATXI) (“Avenue”), a company focused on the development of intravenous (“IV”) tramadol for the U.S. market, today announced the following publications in peer-reviewed journals. The publication titled “Intravenous Tramadol is Effective in the Management of Postoperative Pain Following Abdominoplasty: A Three-Arm Randomized Placebo- and Active-Controlled Trial” has been published in Drugs in R&D and can be acc

Single dose of CD45-ADC shown to remove disease-causing cells and halt disease in models of multiple sclerosis, systemic sclerosis and inflammatory arthritis -- -- MGTA-145 Phase 1 clinical data for stem cell mobilization provide a strong rationale for studying in patients with autoimmune diseases --

Published In Vivo Study Concludes Hemovent’s MOBYBOX™ ECLS Device Provides “Excellent (Long-Term) Safety and Physiologic Efficacy”

The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax Inc. (NASDAQ: NVAX),

Apellis Pharmaceuticals, Inc., a global biopharmaceutical company pioneering targeted C3 therapies, announced that the company approved the grant of equity awards to four new employees with a grant date of June 1, 2020, as an equity inducement award outside of the company’s 2017 Stock Incentive Plan and material to the employees’ acceptance of employment with the company.

Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology both in vivo and ex vivo , today announced the closing of an underwritten public offering of 6,301,370 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 821,917 shares, at the public offering price of $18.25 per share. The

BioMarker Strategies, LLC, a company focused on helping make precision medicine more of a reality for patients with solid tumor cancers, today announced that President and CEO Jerry Parrott will present at BIO Digital. BIO Digital replaces BIO 2020, the Biotechnology Innovation Organization’s International Convention, which was originally scheduled